CONFERENCE
Date: November 15-16, 2012
City: Istanbul, Turkey
Event type: Round Table
REGISTER NOW
|
|
La Merie Publishing
La Merie Business Intelligence is focused on Research and Development in the Biopharmaceutical Industry. La Merie provides information about biopharmaceutical R&D and competitive intelligence. The information is retrieved from La Merie’s in house R&D database, news portal and direct, as well as desktop searches. La Merie has a focus on Biologics, including antibodies, proteins, peptides, vaccines, RNA, DNA and cell therapy.
La Merie publishes Competitor Analysis Reports, Brief Reports and Full Reports. The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced. Brief Reports on Target Pipelines include assessment of the scientific, as well as business perspective of new targets. Full reports provide in-depth analysis of product portfolios, R&D pipelines, competitive environment and a critical assessment of the pipeline perspective.
- Market Reports
- News & Press-Releases
Competitor Analysis: Pseudomonas Aeruginosa Vaccines and Therapeutics
May, 2012 · 46 pages
|
US$ 394.00 |
Competitor Analysis: Staphylococcus Aureus Vaccines and Therapeutics
May, 2012 · 45 pages
|
US$ 394.00 |
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012
Mar, 2012 · 231 pages
|
US$ 2,600.00 |
Competitor Analysis: Anti-Obesity Peptides and Biologics
Feb, 2012 · 28 pages
|
US$ 262.00 |
Competitor Analysis: HIV Small Molecule Therapeutics
Dec, 2011 · 100 pages
|
US$ 642.00 |
Competitor Analysis: Cardiovascular Peptides
Dec, 2011 · 45 pages
|
US$ 401.00 |
Competitor Analysis: Anti-Infective Peptides
Dec, 2011 · 44 pages
|
US$ 401.00 |
Coagulation Factors 2011 – Who Does Meet the Market Needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis
Oct, 2011 · 162 pages
|
US$ 3,258.00 |
Competitor Analysis HIV Vaccines
Oct, 2011 · 54 pages
|
US$ 413.00 |
Competitor Analysis Cancer Vaccines
Nov, 2011 · 151 pages
|
US$ 964.00 |
Competitor Analysis: EGF-R Agonists and Antagonists
Sep, 2011 · 73 pages
|
US$ 533.00 |
Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists
Oct, 2011 · 152 pages
|
US$ 800.00 |
Vaccine Pipeline Database: 1-Year Subscription
Oct, 2011 · 274 pages
|
US$ 1,333.00 |
Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
Sep, 2011 · 274 pages
|
US$ 2,632.00 |
Competitor Analysis: IGF-1R Antagonists
Jun, 2011 · 26 pages
|
US$ 275.00 |
Competitor Analysis: Her2 and Her3 Receptor Antagonists
Sep, 2011 · 63 pages
|
US$ 413.00 |
Competitor Analysis: Novel Mitotic Kinase Inhibitors
Sep, 2011 · 62 pages
|
US$ 550.00 |
Competitor Analysis: HDAC Inhibitors
Jul, 2011 · 58 pages
|
US$ 550.00 |
Competitor Analysis: Targeted Therapy of Hepatitis C
Aug, 2011 · 91 pages
|
US$ 826.00 |
Competitor Analysis: PI3K-AKT-mTOR Inhibitors
Jun, 2011 · 100 pages
|
US$ 711.00 |
Competitor Analysis: Hepatitis Vaccines
Jun, 2011 · 96 pages
|
US$ 498.00 |
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors
Jun, 2011 · 75 pages
|
US$ 660.00 |
Competitor Analysis: Adenosine Receptor Agonists & Antagonists
Apr, 2011 · 26 pages
|
US$ 287.00 |
Competitor Analysis Influenza Vaccines
May, 2011 · 123 pages
|
US$ 718.00 |
Competitor Analysis: Targeted Therapy of Diabetes
Apr, 2011 · 114 pages
|
US$ 1,735.00 |
Competitor Analysis: Emerging Diabetes Drugs
Apr, 2011 · 104 pages
|
US$ 870.00 |
RNA Therapeutics Pipeline Database: 1-Year Subscription
Mar, 2011
|
US$ 847.00 |
Competitor Analysis: Targeted Therapy of Obesity
Mar, 2011 · 80 pages
|
US$ 706.00 |
Competitor Analysis RNA Therapeutics in Clinical Development
Mar, 2011
|
US$ 561.00 |
Therapeutic Protein Pipeline Database: 1-Year Subscription
Feb, 2011
|
US$ 1,613.00 |
Competitor Analysis: Cancer Antibodies in Early Clinical Development
Feb, 2011 · 183 pages
|
US$ 1,210.00 |
Competitor Analysis Enzyme Replacement & Enhancement Therapies (ERT)
Feb, 2011 · 49 pages
|
US$ 413.00 |
Competitor Analysis Interferon
Feb, 2011 · 89 pages
|
US$ 619.00 |
Competitor Analysis Therapeutic Proteins: Biosimilars, Biobetters and Biosuperiors
Feb, 2011 · 265 pages
|
US$ 2,187.00 |
Competitor Analysis: Thrombolytics & Fibrinolytics
Jan, 2011 · 36 pages
|
US$ 342.00 |
Competitor Analysis: Insulin
Jan, 2011 · 73 pages
|
US$ 616.00 |
Competitor Analysis: Erythropoietin (EPO)
Jan, 2011 · 76 pages
|
US$ 684.00 |
Competitor Analysis: Coagulation Factors
Jan, 2011 · 139 pages
|
US$ 821.00 |
Competitor Analysis: Human Growth Hormone (hGH)
Jan, 2011 · 44 pages
|
US$ 454.00 |
Competitor Analysis: G-CSF & GM-CSF
Jan, 2011 · 40 pages
|
US$ 454.00 |
Competitor Analysis Antibody Therapy of Inflammatory and Autoimmune Diseases
Dec, 2010 · 172 pages
|
US$ 1,184.00 |
Competitor Analysis Interleukin-6 (IL-6) and Receptor (IL-6R) Antagonists
Nov, 2010 · 20 pages
|
US$ 205.00 |
Competitor Analysis: Interleukin-1 (IL-1) and Receptor (IL-1R) Antagonists
Nov, 2010 · 22 pages
|
US$ 205.00 |
Competitor Analysis p38 MAPK Inhibitors
Nov, 2010 · 21 pages
|
US$ 273.00 |
Antibody Pipeline Database: 1-Year Subscription
Nov, 2010
|
US$ 1,638.00 |
Antibody Technology Companies 2010 - A systematic guide through the landscape of antibody technologies and their providers
Nov, 2010 · 283 pages
|
US$ 1,394.00 |
Competitor Analysis: Sphingosine-1-Phosphate (S1P)
Nov, 2010 · 26 pages
|
US$ 277.00 |
Competitor Analysis: C5a-R Antagonists
Oct, 2010 · 14 pages
|
US$ 173.00 |
Competitor Analysis: Janus Kinase (JAK) Inhibitors
May, 2012 · 44 pages
|
US$ 394.00 |
Competitor Analysis Toll-Like Receptor (TLR) Agonists & Antagonists
Oct, 2010 · 144 pages
|
US$ 800.00 |
|
|
